Related Experiment Video
Updated: Jul 8, 2026
07:51
A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
Published on: June 18, 2018
Association between heroin dependence and 5-HT2A receptor gene polymorphisms
P A Sáiz1, M P García-Portilla, C Arango
1Department of Psychiatry, School of Medicine, University of Oviedo, Oviedo, Spain. frank@uniovi.es
European Addiction Research
|January 10, 2008
Summary
Genetic variations in serotonin receptor (5-HT2A) and transporter (5-HTT) genes are linked to heroin dependence. The 5-HT2A gene may increase susceptibility, potentially with a synergistic effect from 5-HTT genes.
Area of Science:
- Neurogenetics
- Psychiatric Genetics
- Molecular Psychiatry
Background:
- Serotonin system gene polymorphisms are implicated in substance use disorders.
- Understanding genetic contributions to heroin dependence is crucial for developing targeted interventions.
Purpose of the Study:
- To investigate the association between specific polymorphisms in the serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) genes and heroin dependence.
- To explore potential synergistic effects of these gene polymorphisms on heroin dependence susceptibility.
Main Methods:
- Genotyping of 113 heroin-dependent patients and 420 healthy controls from Northern Spain.
- Analysis of four polymorphisms in the 5-HT2A receptor and 5-HTT genes using standard genotyping techniques.
Main Results:
- The 5-HT2A -1438A allele was significantly more prevalent in heroin-dependent patients (corrected p = 0.042).
- An interaction between 5-HT2A and 5-HTT gene polymorphisms was observed, enhancing the association with heroin dependence in the presence of specific alleles (corrected p = 0.045).
Conclusions:
- The 5-HT2A gene contributes to susceptibility to heroin dependence.
- A synergistic effect between 5-HT2A and 5-HTT genes may influence heroin dependence risk.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...